Pharma firms Sanofi and GlaxoSmithKline say they will begin production of another potential vaccine against COVID-19 within weeks
Production of another potential vaccine against PARIS – COVID-19 will begin within weeks, with its developers Sanofi and GlaxoSmithKline saying on Thursday that they have nominated 35,000 adult volunteers in the United States, Asia, Africa and Latin America as one Started the big test.
If the test is successful, regulators can approve the vaccine for use in the last three months of the year, drug manufacturers said in a statement.
“Construction will begin in the coming weeks to enable faster access to the vaccine, should it be approved,” he said.
His statement quoted Thomas Triumph, who leads vaccine research and development at Sanofi Pasteur, as saying: “Encouraged us to begin the first vaccination in such an important, critical Phase 3 study Goes.”
Earlier this month, firms said their vaccine candidate triggered a strong immune response in all adult age groups in preliminary tests after an earlier setback, a shot to boost optimism this year could join the fight against the epidemic is.
After two doses of the vaccine candidate, participants showed antibodies corresponding to antibodies found in people recovering from the disease, according to previous, small trial results.
Follow all epidemic coverage of AP https://apnews.com/hub/coronavirus-pandemic, https://apnews.com/hub/coronavirus-vaccine and https://apnews.com/UnderstandingtheOutbreak